Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Smoldering Multiple Myeloma 1

Interventions

Specimen Handling 602 pembrolizumab 557 Magnetic Resonance Spectroscopy 527 Carboplatin 422 Cyclophosphamide 370 Cisplatin 369 Biopsy 349 Paclitaxel 304 Gemcitabine 299 Nivolumab 298 Radiotherapy 256 Bevacizumab 232 Dexamethasone 207 fludarabine 203 Docetaxel 185 durvalumab 177 atezolizumab 172 Oxaliplatin 170 Fluorouracil 166 venetoclax 164 Rituximab 163 Pemetrexed 161 Doxorubicin 157 Radiation 155 Capecitabine 155 Radiosurgery 145 Etoposide 137 Leucovorin 133 Ipilimumab 132 Lenalidomide 129

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × IPH-2101 × 90 days × Clear all

NCT01222286 2026-05-14

KIRMONO

Innate Pharma

Phase 2 Completed

30 enrolled 10 charts

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡